Delcath Systems Inc
DCTH11.270USD
+0.680+6.42%
收盘 08/04, 16:00（美东）报价延迟15分钟
376.83M总市值
亏损市盈率 TTM
关于 Delcath Systems Inc 公司
Delcath Systems, Inc. 是一家专注于治疗原发性和转移性肝癌的介入肿瘤学公司。该公司的产品 HEPZATO KIT（注射用 Hepzato（美法仑）/肝脏输送系统）和 CHEMOSAT 美法仑肝脏输送系统（CHEMOSAT）经皮肝灌注 (PHP) 旨在向肝脏施用高剂量化疗药物，同时在 PHP 过程中控制全身暴露和相关副作用。HEPZATO KIT 是一种药物/设备组合产品，旨在将高剂量化疗药物直接输送到肝脏，同时限制全身暴露和相关副作用。在欧洲，肝脏输送系统是一种独立的医疗设备，具有与 HEPZATO KIT 相同的设备组件，但没有盐酸美法仑，并以 CHEMOSAT 的商品名获准销售。在美国，HEPZATO 受美国食品药品管理局 (FDA) 的药品监管。
公司简介
公司代码DCTH
公司名称Delcath Systems Inc
上市日期Oct 19, 2000
CEOMr. Gerard J. Michel
员工数量96
证券类型Ordinary Share
年结日Oct 19
公司地址566 Queensbury Avenue
城市QUEENSBURY
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编12804
电话15187438892
网址https://delcath.com/
公司代码DCTH
上市日期Oct 19, 2000
CEOMr. Gerard J. Michel
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Chief Executive Officer, Director
Chief Executive Officer, Director
319.33K
--
Ms. Sandra Pennell
Ms. Sandra Pennell
Chief Financial Officer
Chief Financial Officer
70.30K
+15.15%
Mr. Kevin Muir
Mr. Kevin Muir
General Manager - Interventional Oncology
General Manager - Interventional Oncology
21.61K
+16.30%
Mr. John Richard Sylvester
Mr. John Richard Sylvester
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
10.55K
--
Ms. Martha S. Rook, Ph.D.
Ms. Martha S. Rook, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. David Hoffman
Mr. David Hoffman
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Dr. Vojislav Vukovic, M.D., Ph.D.
Dr. Vojislav Vukovic, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Mr. Steven A.J. Salamon
Mr. Steven A.J. Salamon
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Chief Executive Officer, Director
Chief Executive Officer, Director
319.33K
--
Ms. Sandra Pennell
Ms. Sandra Pennell
Chief Financial Officer
Chief Financial Officer
70.30K
+15.15%
Mr. Kevin Muir
Mr. Kevin Muir
General Manager - Interventional Oncology
General Manager - Interventional Oncology
21.61K
+16.30%
Mr. John Richard Sylvester
Mr. John Richard Sylvester
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
10.55K
--
Ms. Martha S. Rook, Ph.D.
Ms. Martha S. Rook, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. David Hoffman
Mr. David Hoffman
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
业务USD
名称
营收
占比
HEPZATO KIT
18.02M
91.10%
CHEMOSAT
1.76M
8.90%
暂无数据
业务
地区
业务USD
名称
营收
占比
HEPZATO KIT
18.02M
91.10%
CHEMOSAT
1.76M
8.90%
股东统计
更新时间: 7月31日 周四
更新时间: 7月31日 周四
持股股东
股东类型
持股股东
持股股东
占比
Rosalind Advisors, Inc.
9.80%
The Vanguard Group, Inc.
4.00%
Deerfield Management Company, L.P.
2.33%
Vivo Capital, LLC
2.15%
ExodusPoint Capital Management, LP
2.01%
Other
79.70%
持股股东
持股股东
占比
Rosalind Advisors, Inc.
9.80%
The Vanguard Group, Inc.
4.00%
Deerfield Management Company, L.P.
2.33%
Vivo Capital, LLC
2.15%
ExodusPoint Capital Management, LP
2.01%
Other
79.70%
股东类型
持股股东
占比
Hedge Fund
22.58%
Investment Advisor
12.55%
Investment Advisor/Hedge Fund
3.65%
Individual Investor
2.73%
Venture Capital
2.66%
Research Firm
2.04%
Private Equity
1.33%
Pension Fund
0.40%
Other
52.05%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
177
16.69M
47.96%
-955.13K
2025Q1
171
16.12M
46.80%
-1.98M
2024Q4
141
14.61M
45.75%
-298.57K
2024Q3
113
11.18M
39.89%
-3.98M
2024Q2
94
11.26M
40.31%
-2.23M
2024Q1
81
9.17M
35.81%
-967.18K
2023Q4
82
7.09M
31.51%
-2.72M
2023Q3
76
8.38M
57.84%
+174.15K
2023Q2
68
6.41M
45.63%
+3.12M
2023Q1
64
2.03M
20.29%
-877.12K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Rosalind Advisors, Inc.
3.41M
9.8%
+513.08K
+17.69%
May 05, 2025
The Vanguard Group, Inc.
1.39M
4%
+169.26K
+13.82%
Mar 31, 2025
Deerfield Management Company, L.P.
813.11K
2.33%
+813.11K
--
Mar 31, 2025
Vivo Capital, LLC
750.20K
2.15%
-958.38K
-56.09%
Mar 31, 2025
ExodusPoint Capital Management, LP
699.35K
2.01%
+647.65K
+1252.79%
Mar 31, 2025
Susquehanna International Group, LLP
557.40K
1.6%
+138.79K
+33.16%
Mar 31, 2025
Gilder Gagnon Howe & Co. LLC
538.50K
1.55%
-73.73K
-12.04%
Mar 31, 2025
Perceptive Advisors LLC
462.42K
1.33%
+412.42K
+824.84%
Mar 31, 2025
Millennium Management LLC
422.07K
1.21%
+107.39K
+34.13%
Mar 31, 2025
Invesco Capital Management LLC
399.39K
1.15%
+399.39K
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Simplify Propel Opportunities ETF
2.14%
SPDR S&P Health Care Equipment ETF
0.75%
Invesco Dorsey Wright SmallCap Momentum ETF
0.66%
ALPS Medical Breakthroughs ETF
0.32%
iShares Micro-Cap ETF
0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
ProShares Hedge Replication ETF
0.02%
ProShares UltraPro Russell2000
0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
查看更多
Simplify Propel Opportunities ETF
占比2.14%
SPDR S&P Health Care Equipment ETF
占比0.75%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0.66%
ALPS Medical Breakthroughs ETF
占比0.32%
iShares Micro-Cap ETF
占比0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.05%
ProShares Hedge Replication ETF
占比0.02%
ProShares UltraPro Russell2000
占比0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0.02%
iShares Russell 2000 Growth ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
